• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias.鉴定 M2 毒蕈碱乙酰胆碱受体的变构和变构部位突变,这些突变导致配体选择性信号转导偏倚。
J Biol Chem. 2010 Mar 5;285(10):7459-74. doi: 10.1074/jbc.M109.094011. Epub 2010 Jan 5.
2
G protein coupling and signaling pathway activation by m1 muscarinic acetylcholine receptor orthosteric and allosteric agonists.M1毒蕈碱型乙酰胆碱受体的正构和变构激动剂介导的G蛋白偶联及信号通路激活
J Pharmacol Exp Ther. 2008 Nov;327(2):365-74. doi: 10.1124/jpet.108.141788. Epub 2008 Jul 29.
3
Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors.M2型毒蕈碱型乙酰胆碱受体变构激动作用的结构-功能研究
Mol Pharmacol. 2007 Aug;72(2):463-76. doi: 10.1124/mol.107.037630. Epub 2007 May 24.
4
Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor.新型 M1 毒蕈碱型乙酰胆碱受体选择性激动剂的变构和变构外作用模式。
Mol Pharmacol. 2010 Jul;78(1):94-104. doi: 10.1124/mol.110.064345. Epub 2010 Apr 22.
5
The M1 muscarinic receptor allosteric agonists AC-42 and 1-[1'-(2-methylbenzyl)-1,4'-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site.M1 毒蕈碱型乙酰胆碱受体变构激动剂 AC-42 和 1-[1'-(2-甲基苄基)-1,4'-联哌啶-4-基]-1,3-二氢-2H-苯并咪唑-2-酮与乙酰胆碱正位构象结合位点不同的独特结合位点结合。
Mol Pharmacol. 2010 Oct;78(4):648-57. doi: 10.1124/mol.110.065771. Epub 2010 Jul 21.
6
A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand.G蛋白偶联受体功能选择性的一种新机制。毒蕈碱部分激动剂McN-A-343作为一种双位点正构/别构配体。
J Biol Chem. 2008 Oct 24;283(43):29312-21. doi: 10.1074/jbc.M803801200. Epub 2008 Aug 22.
7
Role of Conserved Tyrosine Lid Residues in the Activation of the M Muscarinic Acetylcholine Receptor.保守的酪氨酸盖残基在 M 毒蕈碱型乙酰胆碱受体激活中的作用。
Mol Pharmacol. 2023 Sep;104(3):92-104. doi: 10.1124/molpharm.122.000661. Epub 2023 Jun 22.
8
Molecular mechanisms of bitopic ligand engagement with the M1 muscarinic acetylcholine receptor.双位配体与M1毒蕈碱型乙酰胆碱受体结合的分子机制
J Biol Chem. 2014 Aug 22;289(34):23817-37. doi: 10.1074/jbc.M114.582874. Epub 2014 Jul 8.
9
Contrasting effects of allosteric and orthosteric agonists on m1 muscarinic acetylcholine receptor internalization and down-regulation.变构激动剂和正构激动剂对M1毒蕈碱型乙酰胆碱受体内化和下调的对比作用。
J Pharmacol Exp Ther. 2009 Dec;331(3):1086-95. doi: 10.1124/jpet.109.160242. Epub 2009 Sep 18.
10
Stimulus bias provides evidence for conformational constraints in the structure of a G protein-coupled receptor.刺激偏倚为 G 蛋白偶联受体结构中的构象约束提供了证据。
J Biol Chem. 2012 Oct 26;287(44):37066-77. doi: 10.1074/jbc.M112.408534. Epub 2012 Sep 10.

引用本文的文献

1
Molecular basis of ligand binding and receptor activation at the human A adenosine receptor.人类A1腺苷受体配体结合及受体激活的分子基础
Nat Commun. 2025 Aug 18;16(1):7674. doi: 10.1038/s41467-025-62872-x.
2
Comparative in vitro and in silico evaluation of the toxic effects of metformin and/or ascorbic acid, new treatment options in the treatment of Melasma.二甲双胍和/或抗坏血酸对黄褐斑治疗的新选择的毒性作用的体外和计算机模拟比较评估
Toxicol Res (Camb). 2025 Feb 27;14(1):tfaf025. doi: 10.1093/toxres/tfaf025. eCollection 2025 Feb.
3
Voltage Sensors Embedded in G Protein-Coupled Receptors.电压传感器嵌入在 G 蛋白偶联受体中。
Int J Mol Sci. 2024 May 13;25(10):5295. doi: 10.3390/ijms25105295.
4
Nanobody-Mediated Dualsteric Engagement of the Angiotensin Receptor Broadens Biased Ligand Pharmacology.纳米抗体介导的血管紧张素受体双位结合拓宽了偏向配体的药理学。
Mol Pharmacol. 2024 Feb 15;105(3):260-271. doi: 10.1124/molpharm.123.000797.
5
Quantitative receptor model for responses that are left- or right-shifted versus occupancy (are more or less concentration sensitive): the SABRE approach.针对左移或右移反应与占有率(浓度敏感性或多或少)的定量受体模型:SABRE方法。
Front Pharmacol. 2023 Dec 15;14:1274065. doi: 10.3389/fphar.2023.1274065. eCollection 2023.
6
Structure-Activity Assessment and In-Depth Analysis of Biased Agonism in a Set of Phenylalkylamine 5-HT Receptor Agonists.一组苯乙胺 5-HT 受体激动剂的偏向激动作用的结构-活性评估和深入分析。
ACS Chem Neurosci. 2023 Aug 2;14(15):2727-2742. doi: 10.1021/acschemneuro.3c00267. Epub 2023 Jul 20.
7
Pharmacological hallmarks of allostery at the M4 muscarinic receptor elucidated through structure and dynamics.通过结构和动力学研究揭示 M4 毒蕈碱受体变构作用的药理学特征。
Elife. 2023 May 30;12:e83477. doi: 10.7554/eLife.83477.
8
Location bias contributes to functionally selective responses of biased CXCR3 agonists.位置偏差导致偏 CXCR3 激动剂的功能选择性反应。
Nat Commun. 2022 Oct 4;13(1):5846. doi: 10.1038/s41467-022-33569-2.
9
Synergistic regulation mechanism of iperoxo and LY2119620 for muscarinic acetylcholine M2 receptor.过氧亚硝酸阴离子与LY2119620对毒蕈碱型乙酰胆碱M2受体的协同调节机制
RSC Adv. 2018 Apr 9;8(24):13067-13074. doi: 10.1039/c8ra01545g.
10
How Do Modulators Affect the Orthosteric and Allosteric Binding Pockets?调节剂如何影响变构结合口袋和正构结合口袋?
ACS Chem Neurosci. 2022 Apr 6;13(7):959-977. doi: 10.1021/acschemneuro.1c00749. Epub 2022 Mar 17.

本文引用的文献

1
Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties.M4 毒蕈碱型乙酰胆碱受体变构调节剂的作用机制及其体内验证,具有潜在的抗精神病特性。
Neuropsychopharmacology. 2010 Mar;35(4):855-69. doi: 10.1038/npp.2009.194. Epub 2009 Nov 25.
2
Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs.正构/别构双位点配体:在G蛋白偶联受体领域走向混合型
Mol Interv. 2009 Jun;9(3):125-35. doi: 10.1124/mi.9.3.6.
3
Allosteric modulation of muscarinic acetylcholine receptors.变构调节毒蕈碱型乙酰胆碱受体。
Curr Neuropharmacol. 2007 Sep;5(3):157-67. doi: 10.2174/157015907781695946.
4
Mutagenic mapping suggests a novel binding mode for selective agonists of M1 muscarinic acetylcholine receptors.诱变图谱揭示了M1毒蕈碱型乙酰胆碱受体选择性激动剂的一种新型结合模式。
Mol Pharmacol. 2009 Feb;75(2):331-41. doi: 10.1124/mol.108.050963. Epub 2008 Nov 11.
5
Overlapping binding site for the endogenous agonist, small-molecule agonists, and ago-allosteric modulators on the ghrelin receptor.内源性激动剂、小分子激动剂和前变构调节剂在胃饥饿素受体上的重叠结合位点。
Mol Pharmacol. 2009 Jan;75(1):44-59. doi: 10.1124/mol.108.049189. Epub 2008 Oct 15.
6
Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity.双构象G蛋白偶联受体靶向作用:实现结合和信号传导途径选择性的新途径。
FASEB J. 2009 Feb;23(2):442-50. doi: 10.1096/fj.08-114751. Epub 2008 Oct 8.
7
Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats.新型M1毒蕈碱型乙酰胆碱受体选择性变构激活剂可调节淀粉样蛋白加工并在大鼠中产生抗精神病样活性。
J Neurosci. 2008 Oct 8;28(41):10422-33. doi: 10.1523/JNEUROSCI.1850-08.2008.
8
A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand.G蛋白偶联受体功能选择性的一种新机制。毒蕈碱部分激动剂McN-A-343作为一种双位点正构/别构配体。
J Biol Chem. 2008 Oct 24;283(43):29312-21. doi: 10.1074/jbc.M803801200. Epub 2008 Aug 22.
9
New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug).利用新型变构调节剂和DREADD(仅由设计药物激活的设计受体)对M4毒蕈碱型乙酰胆碱受体功能的新见解。
Mol Pharmacol. 2008 Oct;74(4):1119-31. doi: 10.1124/mol.108.049353. Epub 2008 Jul 15.
10
Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1.一种可穿透中枢神经系统的选择性M1毒蕈碱受体激动剂77-LH-28-1的特性
Br J Pharmacol. 2008 Jul;154(5):1104-15. doi: 10.1038/bjp.2008.152. Epub 2008 May 5.

鉴定 M2 毒蕈碱乙酰胆碱受体的变构和变构部位突变,这些突变导致配体选择性信号转导偏倚。

Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias.

机构信息

Department of Pharmacology, Monash University, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria 3052, Australia.

出版信息

J Biol Chem. 2010 Mar 5;285(10):7459-74. doi: 10.1074/jbc.M109.094011. Epub 2010 Jan 5.

DOI:10.1074/jbc.M109.094011
PMID:20051519
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2844194/
Abstract

Muscarinic acetylcholine receptors contain at least one allosteric site that is topographically distinct from the acetylcholine, orthosteric binding site. Although studies have investigated the basis of allosteric modulation at these receptors, less is known about putative allosteric ligands that activate the receptor in their own right. We generated M(2) muscarinic acetylcholine receptor mutations in either the orthosteric site in transmembrane helices 3 and 6 (TM3 and -6) or part of an allosteric site involving the top of TM2, the second extracellular (E2) loop, and the top of TM7 and investigated their effects on the binding and function of the novel selective (putative allosteric) agonists (AC-42 (4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)piperidine HCl), 77-LH-28-1 (1-(3-(4-butyl-1-piperidinyl)propyl)-3,3-dihydro-2(1H)-quinolinone), and N-desmethylclozapine) as well as the bitopic orthosteric/allosteric ligand, McN-A-343 (4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium). Four classes of agonists were identified, depending on their response to the mutations, suggesting multiple, distinct modes of agonist-receptor interaction. Interestingly, with the exception of 77-LH-28-1, allosteric site mutations had no effect on the affinity of any of the agonists tested, but some mutations in the E2 loop influenced the efficacy of both orthosteric and novel selective agonists, highlighting a role for this region of the receptor in modulating activation status. Two point mutations (Y104(3.33)A (Ballesteros and Weinstein numbers in superscript) in the orthosteric and Y177A in the allosteric site) unmasked ligand-selective and signaling pathway-selective effects, providing evidence for the existence of pathway-specific receptor conformations. Molecular modeling of 77-LH-28-1 and N-desmethylclozapine yielded novel binding poses consistent with the possibility that the functional selectivity of such agents may arise from a bitopic mechanism.

摘要

毒蕈碱型乙酰胆碱受体至少包含一个变构结合位点,该位点在拓扑结构上不同于乙酰胆碱的正位结合位点。尽管已有研究探讨了这些受体的变构调节基础,但对于能够以自身方式激活受体的假定变构配体知之甚少。我们在跨膜螺旋 3 和 6(TM3 和 -6)中的正位结合位点或涉及 TM2 顶部、第二细胞外(E2)环和 TM7 顶部的变构结合位点的一部分中生成了 M2 毒蕈碱型乙酰胆碱受体突变体,并研究了它们对新型选择性(假定变构)激动剂(AC-42(4-正丁基-1-(4-(2-甲基苯基)-4-氧代-1-丁基)哌啶盐酸盐)、77-LH-28-1(1-(3-(4-正丁基-1-哌啶基)丙基)-3,3-二氢-2(1H)-喹啉酮)和 N-去甲氯氮平)以及双位点正位/变构配体 McN-A-343(4-(间氯苯甲酰基氨甲酰氧基)-2-丁炔基三甲基铵)的结合和功能的影响。根据对突变的反应,鉴定了四类激动剂,这表明存在多种不同的激动剂-受体相互作用模式。有趣的是,除了 77-LH-28-1 之外,变构结合位点的突变对测试的任何激动剂的亲和力都没有影响,但 E2 环中的一些突变影响了正位和新型选择性激动剂的效力,这突出了该受体区域在调节激活状态方面的作用。两个点突变(正位的 Y104(3.33)A(超脚本中的 Ballesteros 和 Weinstein 编号)和变构位点的 Y177A)揭示了配体选择性和信号转导途径选择性效应,为存在途径特异性受体构象提供了证据。77-LH-28-1 和 N-去甲氯氮平的分子建模产生了新的结合构象,这表明此类药物的功能选择性可能源于双位点机制。